In Phase II Clinical Trials
Development of Effective and Innovative Medicines to Address the needs of Patients and Improve their Health, Longevity and Quality of Life.
Hub Controls
  • Demo Video
  • Upload Photo
  • Edit Company Profile
  • Add a Link
  • Update Fast Facts
  • Add Management Bios
  • Private Messages
  • Edit My Profile
  • View/Edit My Portfolio

Email Updates

AlphaRx > Message
Generic_profile

Re: What gives?

Posted by: helloalpha on October 24, 2007 05:52PM

In response to: Re: What gives? by mavenwood

Good comparison mavenwood. DDD has a market cap of $130M vs. ALRX' $7.8M. They don't even have a drug in Phase II. Looks like $0.13 is really a bargain.
Post a Reply

Please login to reply to this message.

Executive Address
Alrxsmall
Michael Lee
President
May 18, 2006

 

Michael Lee provides the investor community an update on recent events

View Broadcast

Stock Quote